An der Goldgrube 12
BioNTech AG is Europe’s largest privately held biopharmaceutical company pioneering the development of individualized therapies for cancer and other diseases.
Founders: Ugur Sahin and Christoph Huber
Founder and CEO: Ugur Sahin
COO: Sean Marett
CFO: Sierk Poetting
40 articles with BioNTech
In addition to the planned BioNTech IPO, many other pharma and biotech companies in Europe, Asia and elsewhere shared news for the week.
For BioNTech, the IPO will follow a funding round that brought about $270 million into the coffers of the privately-held company.
Biotech and pharma companies from across the globe share data and news in a weekly roundup.
Messenger RNA (mRNA) is a family of RNA molecules that transport genetic information from DNA to the ribosome, where it specifies the amino acid sequence that creates proteins. In theory, by coding your own mRNA, it should be possible to insert it into the cells and turn them into protein factori...
BioNTech AG and MAB Discovery GmbH announced that both partners have entered into a definitive agreement under which BioNTech will acquire MAB Discovery’s operational antibody generation unit.
BioNTech AG inked a deal with Munich, Germany’s MAB Discovery GmbH to acquire MAB’s operational antibody generation unit. No financial details were disclosed.
Days ahead of the J.P. Morgan Healthcare Conference, Germany-based BioNTech extended its three-year-old collaboration with Sanofi as the companies look to co-develop the first cancer immunotherapy candidate for solid tumors.
BioNTech: MammaTyper® Validated as Predictor for Response After Neoadjuvant Chemotherapy (NACT) in Patients with Early Breast Cancer (BC)
New results from a clinical performance evaluation study of the CE-marked IVD MammaTyper® which were presented at the European Society for Medical Oncology (ESMO) in Munich in October.(1,2)
BioNTech and the University of Pennsylvania Enter into Strategic Research Collaboration to Develop mRNA Vaccine Candidates Against Various Infectious Diseases
New research program between BioNTech and the University of Pennsylvania
8/16/2018BioNTech, headquartered in Mainz, Germany, and Pfizer, based in New York City, signed a multi-year research-and-development deal to develop mRNA-based flu vaccines.
BioNTech Signs Collaboration Agreement with Pfizer to Develop mRNA-based Vaccines for Prevention of Influenza
BioNTech will receive $120 million in upfront, equity and near-term research payments from Pfizer and will be eligible to receive up to $305 million in potential development, regulatory and commercial milestone payments and up to double-digit royalties
Pursuing a common objective of superior primary packaging for a range of mRNA compounds
BioNTech AG and Genevant Sciences entered into a strategic partnership to develop five therapeutics to treat rare diseases.
Partnership combines Genevant’s industry-leading delivery technology and BioNTech’s cutting-edge mRNA drug discovery platform to develop best-in-class therapeutics
Changes continue coming to Vivek Ramaswamy’s Roivant Sciences following a June shakeup that saw a 10 percent cut in employment and the restructuring of its business operations.
Arbutus Biopharma Corporation today announced updates on several key milestones in advance of the company’s presentation at Roivant Pipeline Day in New York City this afternoon.
Translate Bio, headquartered in Lexington, Massachusetts, and Paris-based Sanofi are teaming up to develop five vaccines.
BioNTech Announces Results from Two More Studies Demonstrating the Benefits of Breast Cancer Subtyping Using Mammatyper
The results of these studies again demonstrate the benefits of breast cancer subtyping using MammaTyper to predict the course of the disease and to aid in the selection of effective, tailored therapy.
A look at whether big money and big deals will be in store for 2018.
The Company previously completed a seed round fundraising in 2008 concurrent with its founding.